Used to select potentially responsive patients for clinical trials on new drugs or combinations to greatly increase success of drug development, reduce attrition rate and potentially rescue abandoned cancer drug candidates Identification of new drug combinations likely to benefit cancer patients Develop efficient strategies to identify additional combinations for better efficacy and less toxicity
Our Biofunctional Evaluation of Anticancer Therapies (BEAT) is a chemosensitivity test performed in our CLIA registered lab. We treat amplified patient tumor cells in-vitro with large numbers of singular drugs or combinations of drugs. We then measure the cancer cell death rate over time to determine which drugs are effective. This test guides treatment at any stage of a patient's cancer.
How tumor cells respond to treatments in real-time will show if the patient's tumor will be resistant to the drugs during treatment. If a treatment kills tumor cells in-vitro, then patients are more likely to get a response. However, if a treatment does not kill tumor cells in-vitro, then patients will not respond. This does not mean the patient will get the same cancer-cell death rate during treatment. Further clinical trials will elucidate patient responses in-vivo.
Genomic testing helps only to a small percentage of patients, because only a small percentage of patients have actionable mutations. However, BEATtumor℠ directly tests how tumor cells respond to treatments.
Test single drugs or combinations of drugs to simulate real treatments. We generate a limitless supply of patient cancer cells, so you can test a limitless amount of treatments.
We have identified many new drug combinations that are likely to benefit cancer patients and have developed efficient strategies to identify additional combinations for better efficacy and less toxicity.
Currently, BEATtumor℠ and our other services are offered for research purposes only. If you are interested in using our product for research, please contact us for more information.
We are actively looking to partner with companies who want to make our services better and advance cancer research. BEATtumor℠ is an enormous asset to any drug company looking to go into clinical trials, or to any drug company that has failed a clinical trial. BEATtumor℠ can be used to select potentially responsive patients for clinical trials on new drugs or combinations, greatly increasing the success of drug development, and therefore reducing attrition rate. Companies whose drugs have failed clinical trials can rescue those drugs by identifying new patient populations
We have identified many new drug combinations that are likely to benefit cancer patients and have developed efficient strategies to identify additional combinations for better efficacy and less toxicity. We have a standard set and cancer-specific sets of treatments we test, but we also work with the physician to customize the list of drugs we use to test on their patient's own tumor cells.
We are a CLIA registered lab. We will become a CLIA certified lab in July of 2019. Until then, we can only offer our services for research only.
We are working on evaluating BEATtumor℠ in clinical trials to provide more treatment insights. Successful clinical trials may allow us to provide guidance on dosage, composition of treatments, and reliably compare each treatment to recommend the most effective ones.
Our lab is CLIA Registered. We are preparing to go commercial with BEATtumor℠ as soon as we obtain our CLIA Certification this summer. In the meantime, BEATtumor℠ is for research use only. If you would like more information or are interested in ordering, please fill out the contact form and we will reach out to you.
Rapidly produces a perpetual supply primary cancer cells from a variety of patient tumor specimens.
Store your original tumor or amplified tumor cells in an account that never runs out of living tumor cells.